Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rite Aid Not Required To Have Uniform Rx Pricing, Florida Judge Rules

Executive Summary

Charging different prescription drug prices for cash-paying and third-party covered patients is not an unfair trade practice, Tallahassee, Fla. circuit court Judge Nikki Ann Clark said in dismissing a Florida Attorney General complaint against Rite Aid Feb. 18.

You may also be interested in...

Rite Aid Unofficial Two-Tiered Pricing Targeted In Florida RICO Suit

An unofficial, but allegedly authorized, system used by Rite Aid pharmacists for raising prescription drug prices for cash-paying customers is the subject of a lawsuit filed by the Florida Attorney General's office in Tallahassee Circuit Court on Sept. 22. The state has accused Rite Aid Corp. with overcharging more than 29,000 uninsured patients for their prescription medications. The complaint charges racketeering, civil theft and violations of the state's trade practices act.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts